What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-05-01 compared with 2024-10-31 · 75 added, 35 removed, 17 unchanged (87% of the section changed)

1 unchanged sentence

Trading Plans

During the three months ended September 30, 2024, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:

Name and Title of Director or Officer

Action Date Trading Arrangement Total Shares Available to be Sold

Expiration Date

Rule 10b5-1* Non-Rule 10b5-1**

Michael Raab , President and Chief Executive Officer

Adoption September 4, 2024 X

500,000 January 2, 2026

*Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

**Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

Incorporated by Reference

Number Exhibit Description Form Date Number Filed

During the 2025 first quarter, no director or Section 16 officer adopted or terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements.

Table of Content s

Number Incorporated by Reference Filed

Exhibit Description Form Date Number

3.1 Amended and Restated Certificate of Incorporation.

June 24, 2024 3.1

8-K 06/24/2024 3.1

3.2 Certificate of Amendment to Amended and Restated Certificate of Incorporation.

June 20, 2023 3.1

8-K 06/20/2023 3.1

3.3 Amended and Restated Bylaws.

8-K June 24, 2014 3.2

Commercial Supply Agreement , dated August 7, 2024 and effective as of July 23, 2024, by and between Ardelyx, Inc.

and Catalent.

8-K August 12, 2024 10.1

Commercial Supply Agreement, dated October 25, 2024, by and among Ardelyx, Inc., Hovione Farmaciência, S.A.

and Hovione, LLC .

10.3 Lease Agreement, dated October 3, 2024, by and between Ardelyx, Inc.

and BMR-Pacific Research Center LP.

8-K October 9, 2024 10.1

10.4 Sixth Amendment to Lease, dated May 25, 2021, by and between Ardelyx, Inc.

and 34175 Ardenwood Venture, LLC.

October 9, 2024 10.2

10.5 Fourth Amendment to the Loan and Security Agreement dated October 29, 2024, by and between Ardelyx, Inc.

and SLR Investment Corp.

Offer Letter, dated July 25, 2024 by and between Alderyx, Inc.

and Eric Foster.

8-K 06/24/2014 3.2

Second Amended and Restated Executive Employment Agreement, dated April 29, 2025, by and between Ardelyx, Inc.

and Michael Raab.

Form of Amended and Restated Change in Control and Severance Agreement for Executive Officers Other Than CEO.

Fourth Amended and Restated Non-Employee Director Compensation Program.

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

2 unchanged sentences

101 The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL):

(i) Condensed Balance Sheets as of September 30, 2024 and December 31, 2023, (ii) Condensed Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2024 and 2023, (iii) Condensed Statements of Changes in Stockholders Equity for the three and nine months ended September 30, 2024 and 2023, (iv) Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023, and (v) Notes to Unaudited Condensed Financial Statements.

(i) Condensed Balance Sheets as of March 31, 2025 and December 31, 2024, (ii) Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025 and 2024, (iii) Condensed Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2025 and 2024, (iv) Condensed Statements of Cash Flows for the three months ended March 31, 2025 and 2024, and (v) Notes to Unaudited Condensed Financial Statements.

104 Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.

† Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is the type that the Company treats as private or confidential.

_______________________________

# Indicates management contract or compensatory plan.

1 unchanged sentence

under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

Table of Content s

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Ardelyx, Inc.

October 31, 2024 By:

/s/ Robert Felsch

Robert Felsch

May 1, 2025 By:

/s/ Joseph Reilly

Joseph Reilly

Senior Vice President and Chief Accounting Officer

(Principal Accounting Officer)

Table of Content s

SUMMARY OF ABBREVIATED TERMS

Throughout this Quarterly Report on Form 10-Q, we have used terms which are defined below:

340B Program Public Health Service’s 340B Drug Pricing Program GTN gross-to-net

AAKP American Association of Kidney Patients HCR HealthCare Royalty Partners IV, L.P.

ACA Affordable Care Act HCR Agreement Royalty and Sales Milestone Interest Acquisition Agreement

AI Technologies

Artificial intelligence, machine learning and certain automated decision-making technologies

HHS Department of Health and Human Services

AMP average manufacturer price HIPAA Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder

ANDA abbreviated New Drug Application HRSA Health Resources and Services Administration

2024 Form 10-K

Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 20, 2025

IBS-C irritable bowel syndrome with constipation

API active pharmaceutical ingredient IND Investigational New Drug

AstraZeneca AstraZeneca AB IRA Inflation Reduction Act of 2022

ASU Accounting Standards Update IRB institutional review board

California Consumer Privacy Act, as amended by the California Privacy Rights Act

Jefferies Jefferies, LLC

current Good Manufacturing Practice

Kyowa Kirin Co., Ltd.

CKD chronic kidney disease Knight

Knight Therapeutics, Inc.

CME Chicago Mercantile Exchange MDRP Medicaid Drug Rebate Program

CMO contract manufacturing organization METiS METiS Therapeutics, Inc.

CMS Centers for Medicare & Medicaid Services MHLW Ministry of Health, Labour and Welfare

CRO contract research organization

MIPPA Medicare Improvements for Patients and

Providers Act

Chief Operating Decision Maker

OLC Oxylanthanum Carbonate

collectively, major wholesalers, specialty pharmacies and GPOs (IBSRELA) and specialty wholesaler (XPHOZAH)

NCE new chemical entity

EU-US Data Privacy Framework NDA New Drug Application

EEA European Economic Area NH3 sodium hydrogen exchange 3

ESPP Employee Stock Purchase Plan NMPA National Medical Products Administration

ESRD End-Stage Renal Disease NOL net operating loss

ESRD PPS End-Stage Renal Disease Prospective Payment System NMQF National Minority Quality Forum

EU Patent Package European Patent Package Non-FAMP Non-Federal Average Manufacturer Price

the Securities Exchange Act of 1934, as amended

R&D research and development

FASB Financial Accounting Standards Board REMS Risk Evaluation and Mitigation Strategy

FDA Food and Drug Administration RSU restricted stock units

FFDCA Federal Food, Drug, and Cosmetic Act SLR SLR Investment Corp.

Fosun Pharma Shanghai Fosun Pharmaceutical Industrial Development Co.

SEC Securities and Exchange Commission

FSS Federal Supply Schedule SOFR

Secured Overnight Financing Rate

Federal Trade Commission

TDAPA Transitional Drug Add-on Payment Adjustment

generally accepted accounting principles

UPC European Unified Patent Court

GCP Good Clinical Practice U.S.

United States

GDPR European Union General Data Protection Regulation USPTO U.S.

Patent and Trademark Office

GLP Good Laboratory Practice VA Department of Veterans Affairs

GPO group purchasing organization

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information